This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Stephen B. Thompson Vice President, Chief Financial Officer Access Pharmaceuticals, Inc. (214) 905-5100 Contact: Investor Relations Donald C. Weinberger/Diana Bittner (media) Wolfe Axelrod Weinberger Assoc. LLC (212) 370-4500
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved